Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

被引：31

作者：

Mohty, Razan ^{[1
]}

Dulery, Remy ^{[2
,3
]}

Bazarbachi, Abdul Hamid ^{[4
]}

Savani, Malvi ^{[5
]}

Hamed, Rama Al ^{[4
]}

Bazarbachi, Ali ^{[1
]}

Mohty, Mohamad ^{[2
,3
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol & Oncol, Beirut, Lebanon

[2] St Antoine Hosp, Dept Hematol, AP HP, Paris, France

[3] Sorbonne Univ, Ctr Rech St Antoine CRSA, INSERM, UMRs 938, Paris, France

[4] Albert Einstein Coll Med, Dept Internal Med, Jacobi Med Ctr, New York, NY USA

[5] Univ Arizona, Canc Ctr, Dept Med, Div Hematol & Oncol, Tucson, AZ 85721 USA

来源：

BLOOD CANCER JOURNAL | 2021年 / 11卷 / 07期

关键词：

STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN CONSOLIDATION; POSITRON-EMISSION-TOMOGRAPHY; BONE-MARROW-TRANSPLANTATION; METABOLIC TUMOR VOLUME; QUALITY-OF-LIFE; OPEN-LABEL; PHASE-II; DOSE-INTENSIFICATION; REDUCED-INTENSITY;

D O I：

10.1038/s41408-021-00518-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody-drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.

引用

页数：10

共 77 条

[1] Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma [J].

Allen, Pamela B. ;

Savas, Hatice ;

Evens, Andrew M. ;

Advani, Ranjana H. ;

Palmer, Brett ;

Pro, Barbara ;

Karmali, Reem ;

Mou, Eric ;

Bearden, Jeffrey ;

Dillehay, Gary ;

Bayer, Robert A. ;

Eisner, Robert M. ;

Chmiel, Joan S. ;

O'Shea, Kaitlyn ;

Gordon, Leo I. ;

Winter, Jane N. .

BLOOD, 2021, 137 (10) :1318-1326

[2]

Allen PB, 2020, BLOOD, V137, P1318

[3]

[Anonymous], 2015, BLOOD, DOI [10.1182/blood.V126.23.577.577, DOI 10.1182/BLOOD.V126.23.577.577]

[4] PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation [J].

Armand, Philippe ;

Chen, Yi-Bin ;

Redd, Robert A. ;

Joyce, Robin M. ;

Bsat, Jad ;

Jeter, Erin ;

Merryman, Reid W. ;

Coleman, Kimberly C. ;

Dahi, Parastoo B. ;

Nieto, Yago ;

LaCasce, Ann S. ;

Fisher, David C. ;

Ng, Samuel Y. ;

Odejide, Oreofe O. ;

Freedman, Arnold S. ;

Kim, Austin, I ;

Crombie, Jennifer L. ;

Jacobson, Caron A. ;

Jacobsen, Eric D. ;

Wong, Jeffrey L. ;

Patel, Sanjay S. ;

Ritz, Jerome ;

Rodig, Scott J. ;

Shipp, Margaret A. ;

Herrera, Alex F. .

BLOOD, 2019, 134 (01) :22-29

[5] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[6] CURRENT CONCEPTS Early-Stage Hodgkin's Lymphoma [J].

Armitage, James O. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) :653-662

[7] Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression [J].

Badar, Talha ;

Astle, John ;

Kakar, Imran K. ;

Zellner, Katie ;

Hari, Parameswaran N. ;

Hamadani, Mehdi .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (02) :E98-E101

[8] A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma [J].

Bartlett, Nancy L. ;

Herrera, Alex F. ;

Domingo-Domenech, Eva ;

Mehta, Amitkumar ;

Forero-Torres, Andres ;

Garcia-Sanz, Ramon ;

Armand, Philippe ;

Devata, Sumana ;

Izquierdo, Antonia Rodriguez ;

Lossos, Izidore S. ;

Reeder, Craig ;

Sher, Taimur ;

Chen, Robert ;

Schwarz, Sylvia E. ;

Alland, Leila ;

Strassz, Andras ;

Prier, Kim ;

Choe-Juliak, Cassandra ;

Ansell, Stephen M. .

BLOOD, 2020, 136 (21) :2401-2409

[9] Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study [J].

Bazarbachi, Ali ;

Boumendil, Ariane ;

Finel, Herve ;

Castagna, Luca ;

Dominietto, Alida ;

Blaise, Didier ;

Diez-Martin, Jose L. ;

Tischer, Johanna ;

Gulbas, Zafer ;

Wallet, Helene L. ;

Corral, Lucia L. ;

Mohty, Mohamad ;

Koc, Yener ;

Yakoub-Agha, Ibrahim ;

Schmid, Christoph ;

El Cheikh, Jean ;

Arat, Mutlu ;

Forcade, Edouard ;

Dreger, Peter ;

Rocha, Vanderson ;

Garcia, Gonzalo G. ;

Chalandon, Yves ;

Ferra, Christelle ;

Orvain, Corentin ;

Robinson, Stephen ;

Montoto, Silvia ;

Sureda, Anna .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (05) :745-756

[10] Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party [J].

Bazarbachi, Ali ;

Boumendil, Ariane ;

Finel, Herve ;

Mohty, Mohamad ;

Castagna, Luca ;

Blaise, Didier ;

Peggs, Karl S. ;

Afanasyev, Boris ;

Diez-Martin, J. L. ;

Corradini, Paolo ;

Michonneau, David ;

Robinson, Stephen ;

Gutierrez Garcia, Gonzalo ;

Bonifazi, Francesca ;

Yakoub-Agha, Ibrahim ;

Gulbas, Zafer ;

Bloor, Adrian ;

Delage, Jeremy ;

Esquirol, Albert ;

Malladi, Ram ;

Scheid, Christof ;

El-Cheikh, Jean ;

Ghesquieres, Herve ;

Montoto, Silvia ;

Dreger, Peter ;

Sureda, Anna .

CANCER, 2019, 125 (01) :90-98

← 1 2 3 4 5 6 7 8 →